Attached files
| file | filename |
|---|---|
| 8-K - 8K LAZARD CAPITAL HEALTHCARE CONFERENCE - WEST PHARMACEUTICAL SERVICES INC | form8k.htm |
WEST PHARMACEUTICAL SERVICES, INC.
Solutions for Injectable Drug Delivery NYSE:WST www.westpharma.com
© 2011 by West Pharmaceutical Services, Inc., Lionville, PA.
All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.
Lazard Capital Markets 8th Annual Healthcare Conference
New York, NY
November 16, 2011
Safe Harbor Statement
2
Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
This presentation and any accompanying management commentary contain “forward-looking statements”
as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements about expected financial results for 2011 and future years.
as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements about expected financial results for 2011 and future years.
Each of these estimates is based on preliminary information, and actual results could differ from these
preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.
preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.
Non-GAAP Financial Measures
For the purpose of aiding the comparison of our year-over-year results, we often refer to net sales and
other financial results excluding the effects of changes in foreign exchange rates. These re-measured
results excluding effects from currency translation are not in conformity with U.S. Generally Accepted
Accounting Principles (“U.S. GAAP”) and should not be considered in isolation or as an alternative to
such measures determined in accordance with U.S. GAAP. Additionally, performance measurements
such as compound annual growth rate and gross margin are indicators commonly used in the financial
community, but they are not measures of performance under U.S. GAAP.
other financial results excluding the effects of changes in foreign exchange rates. These re-measured
results excluding effects from currency translation are not in conformity with U.S. Generally Accepted
Accounting Principles (“U.S. GAAP”) and should not be considered in isolation or as an alternative to
such measures determined in accordance with U.S. GAAP. Additionally, performance measurements
such as compound annual growth rate and gross margin are indicators commonly used in the financial
community, but they are not measures of performance under U.S. GAAP.
Pharmaceutical Packaging Systems
Pharmaceutical Delivery Systems
• A globally diverse manufacturer of
products used primarily in containing and
administering small-volume parenteral
drugs.
products used primarily in containing and
administering small-volume parenteral
drugs.
• Strong competitive position
– Substantial market shares
– Proprietary technology
– Diversified customer base
– Global footprint
– Preferred products for biologics
– Long-term customer relationships
• Stability with growth potential
• Proprietary products
• Geographic expansion
• Financial strength to invest
– Reliable operating cash flow
– Well capitalized
3
Sales
($ in millions)
($ in millions)
4
Compound annual growth rate: 4.9% (4.3% ex-currency)
Business Segments
$785
$324
2010 Revenues
($ millions)
Delivery Systems
• Contract manufacturing base
• Multi-material
• Project management
• Automated assembly
• Regulated products
• Capabilities + IP = proprietary
delivery devices
delivery devices
• Proprietary devices are
expected to drive growth
expected to drive growth
Packaging Systems
• Established leadership
• Designed-in revenue base
• Diverse global capabilities
• High market shares
• Steady growth in base
• Increasing unit value of products
and geographic expansion are
expected to enhance growth
and geographic expansion are
expected to enhance growth
5
A Diverse, Stable Customer Base
(representative healthcare customers)
(representative healthcare customers)
PHARMACEUTICAL / BIOTECHNOLOGY
GENERIC
MEDICAL DEVICE
6
• Company
– Demographics and increasing prevalence of chronic disease
– Increasing use of biologics to treat those
– Broader access to healthcare
• Packaging Systems Segment
– Growth in emerging markets
– Products and processes to satisfy escalating regulatory and quality
expectations
expectations
• Delivery Systems Segment
– Demand for combination products that promote safety, dosing accuracy,
ease of use, and deliver cost savings
ease of use, and deliver cost savings
– Drug product life cycle management
– Growing customer & regulatory awareness of glass quality issues
What Will Drive Growth?
7
|
Category
|
Key Customers
|
Projected
Growth |
|
Diabetes
|
|
> 10 %
|
|
Oncology
|
|
> 10 %
|
|
Vaccines
|
|
> 10 %
|
|
Autoimmune
|
|
> 8%
|
|
Generics
|
|
>10%
|
IMS April 2010 Report; Business Insights 2009; GBI Research 2009
Therapeutic Category Growth Drivers
8
Pharmaceutical Packaging Systems
Packaging Components for Small Volume Parenterals
Packaging Components for Small Volume Parenterals
Plungers, Tip Caps,
Needle Shields for Glass
Syringes
Needle Shields for Glass
Syringes
Plungers, Lined
Seals for Glass
Cartridges for Pens
Seals for Glass
Cartridges for Pens
Primary packaging components (those that touch the drug) are typically
proprietary to West and are “designed into” customers’ drug products
proprietary to West and are “designed into” customers’ drug products
9
Packaging Systems Segment
• Increase per-unit value
• Continued growth of prefilled syringes
• Improve operating efficiency: lean operations
• Geographic expansion - capacity investments in Asia
• Strategic acquisitions and partnerships
Growth Strategy
10
Standard High-Value
Products Products
Revenue Opportunity ($ per unit)
Plungers and
sleeve stoppers
sleeve stoppers
Stoppers
Seals
RU seals
Westar® RU
11
Faster Growth of High-Value Products
Pharmaceutical Packaging Systems
Pharmaceutical Packaging Systems
12
Pharmaceutical Packaging Systems
Key High-Value Products
Key High-Value Products
• Westar® RS (ready-to-sterilize) and Westar® RU (ready-to-use)
components
components
• Barrier film coatings (FluroTec®, Teflon® coated) enhance
drug-product stability
drug-product stability
– Key feature for biotech products
• B-2 and LyoTec® coatings for enhanced handling and machinability
• Envision™ 100% vision-inspected products
– Eliminate deformation, surface and embedded defects
Teflon® is a registered trademark of DuPont.
FluroTec® technology is licensed from Daikyo Seiko, Ltd.
FluroTec® technology is licensed from Daikyo Seiko, Ltd.
13
Delivery Systems
ConfiDose®
auto-injector system
auto-injector system
Daikyo Crystal Zenith®
life-cycle containment solutions
life-cycle containment solutions
SmartDose® electronic
patch injector system
patch injector system
MixJect® and
Vial2Bag®
Vial2Bag®
Custom Manufacturing of
Components and Devices
Components and Devices
Proprietary Components, Devices and Systems
14
Delivery Systems Segment
• Realize commercial potential of Crystal Zenith products
• Leverage life-cycle management opportunities
• Develop new platform opportunities - combination products
• Custom solution provider
Growth Strategy
15
Revenue per-unit
Consumer product
manufacturing
manufacturing
Medical device
manufacturing
manufacturing
Mix2Vial®
Crystal
Zenith vials
Zenith vials
Crystal
Zenith syringes
Zenith syringes
ConfiDose®
Effect of Increasing Proprietary Device Sales
Contract Manufacturing Proprietary Devices
Products
SmartDose ®
16
Daikyo Crystal Zenith® Solution
with Daikyo FluroTec® Barrier Film
with Daikyo FluroTec® Barrier Film
• Reduces:
– drug exposure to extractables
– risk of protein aggregation caused by silicone oil in the drug product
– returns and in-process clean-ups caused by broken glass
– risk of delamination and glass-particulate contamination
• Consistent piston release and travel forces without using silicone oil
17
SmartDose®
Electronic Patch Injector
Programmed by PDA or PC
Dose may be customized
Applied and activated by patient
• Controlled, subcutaneous, micro-infusion delivery
of high volumes and high viscosity drugs
of high volumes and high viscosity drugs
• Prefilled cartridge, no need for user filling
• Based on Daikyo Crystal Zenith® cartridge
• Compact
• Hidden needle for safety
• Single push-button operation
Prototype Operation
18
New Product Commercialization
Schematic representation of order and timing of West & Customer activities
Schematic representation of order and timing of West & Customer activities
Commercial Sales:
Rx product approval
and launch (new
product)
and launch (new
product)
Production using
new West product
new West product
Commercial
production
production
1 2 4 5 6
Approximate timing (years)
19
Our Long-Term Focus
• Pharmaceutical Packaging Systems
– Organic growth of 3-5% per year
– Margin expansion from efficiency, product mix
– Capital investments target enhanced quality and value
• Pharmaceutical Delivery Systems
– Deliver the potential of Daikyo Crystal Zenith® products
– Stronger mix of healthcare-consumable contract manufacturing
– Grow proprietary safety and delivery systems
• Financial discipline
– Operating cash flow supports R&D and capital spending
– Deliver returns (ROIC) that regularly exceed cost of capital (WACC)
– Maintain quarterly dividend
– Align incentives with financial performance and value creation
20
Pharmaceutical Packaging Systems
Pharmaceutical Delivery Systems
• Strong competitive position
– Substantial market shares
– Proprietary technology
– Diversified customer base
– Global footprint
– Preferred products for biologics
– Long-term customer
relationships
relationships
• Stability with growth potential
• Proprietary products
• Geographic expansion
• The financial strength to invest
– Reliable operating cash flow
– Well capitalized
Summary
21
On average, approximately 100 million components manufactured by West and
our Global Partners are used to enhance the quality of healthcare worldwide
everyday.
our Global Partners are used to enhance the quality of healthcare worldwide
everyday.
Global Partners with Daikyo Seiko, Ltd. and West Pharmaceutical services Mexico, S.A. de
C.V.
C.V.
22